NSE: IPCALAB | BSE: 524494

Mid-range Performer

Download real time

1367.60 -2.50 (-0.18%)

36,967 NSE+BSE Volume

NSE 02 Sep, 2025 3:47 PM (IST)

34,696.6

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Ipca Laboratories Ltd.

31 May 2017

1367.60

-0.18%

IPCA Laboratories

Hold: Ipca Laboratories Ltd.

Target

ICICI Securities Limited

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

27 Apr 2017

1367.60

-0.18%

Ipca Laboratories Ltd Q4FY17 results comment

Results Update: Ipca Laboratories Ltd.

HDFC Securities

Revenue decreased by 14.31% to Rs. 730.84 Cr in Q3FY17 when compared to the previous quarter.

Prabhudas Lilladhar released a Accumulate report for Ipca Laboratories Ltd. with a price target of 1525.0 on 13 Aug, 2025.

Ipca Laboratories Ltd.

22 Feb 2017

1367.60

-0.18%

Result Updates

Accumulate: Ipca Laboratories Ltd.

Angel Broking

IPCA Labs posted results lower than expected for 3QFY2017 on both sales and net profit fronts, however OPM's were in-line with expectations. In sales, the company posted sales of Rs731cr, a yoy growth of 8.3% v/s Rs815cr expected. On EBITDA front, the company posted EBITDA of 13.9% (v/s 13.5% expected) v/s 11.6% in 3QFY2016. Consequently,..

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

17 Feb 2017

1367.60

-0.18%

Result Update:Ipca Labs.

Buy: Ipca Laboratories Ltd.

Axis Direct

IPCA's Q3 EBITDA at Rs 1.02 bn (up 30% YoY) was in line with our estimate, on account of strong gross margin expansion. However, Q3 PAT was 25% below estimate due to higher tax expense. Domestic formulation witnessed 9% YoY growth, moderately impacted by demonetization. Export businesses growth wa..

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

16 Feb 2017

1367.60

-0.18%

Ipca Laboratories Ltd Q3FY17 results comment

Results Update: Ipca Laboratories Ltd.

HDFC Securities

Revenue fell by 14.31% to Rs. 730.84 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it increased by 8.35% when compared with Q3FY16.

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

13 Feb 2017

1367.60

-0.18%

IPCA Laboratories

Hold: Ipca Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 8% YoY to | 751 crore (I-direct estimate: | 783 crore) mainly due to 9% growth in domestic formulations to | 335 crore (Idirect estimate: | 355 crore). Export formulations grew 6% YoY to | 234 crore (I-direct estimate: | 257 crore) EBITDA margins improved 182 bps YoY to 14.7% (I-direct estimate: 13.7%) on account of a strong gross margin performance. Gross margins increased 357 bps YoY to 66.2% (I-direct estimate: 62.0%) Net profit grew 66% YoY to | 45 crore (I-direct estimate: | 44 crore)...

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

13 Feb 2017

1367.60

-0.18%

IPCA Labs: Q3FY17 Result Review - Lower revenues compensated... (Feb 13, 2017)

Sell: Ipca Laboratories Ltd.

Karvy

In Q3FY17, total revenues of IPCA Labs increased by 8.6%YoY to Rs 7,418mn (our estimates Rs 7598 mn) mainly due to increase in domestic formulations. The Companys operating margins increased by 181 bps YoY to 14.7% (higher than our estimates 14.6%) during the quarter mainly due to higher gross margins and lower staff and overheads. Its net profit has increased by 57% YoY to Rs 413 mn in Q3FY17 higher than our estimates of Rs 326 mn.

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

16 Nov 2016

1367.60

-0.18%

Ipca Laboratories Ltd

Accumulate: Ipca Laboratories Ltd.

Recommendation

Angel Broking

Ipca Laboratories posted numbers lower than expected on the net profit and OPM front. On sales front, the company posted sales of Rs853cr (vs. Rs750cr expected vs. Rs739cr in 2QFY2016), posting a yoy growth of 15.5%. On the operating front, the EBITDA margin came in at 12.8% vs. 14.9% expected vs. 10.6% in 2QFY2016. Consequently, the...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Is Ipca Laboratories Ltd. worth buying?

365 Votes:

Buy 80.27%

Sell 9.86%

Hold 9.86%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf